散发性克雅氏病的体内[18F]-AV-1451 tau-PET显像
在5例尸检证实的散发性克雅氏病患者中进行[18F]-AV-1451 tau-PET显像,并与认知正常者和极轻度阿尔茨海默病痴呆者比较。患者的标准摄取值比与认知正常者无法区分,且远低于阿尔茨海默病者;未观察到独特滞留模式。
要点
- 5例散发性克雅氏病患者[18F]-AV-1451滞留与认知正常者无差异,远低于阿尔茨海默病者。
- 视觉检查未发现散发性克雅氏病独特的[18F]-AV-1451滞留模式。
- [18F]-AV-1451对阿尔茨海默病相关配对螺旋丝tau蛋白保持良好特异性。
核心结论
- 在因散发性克雅氏病导致快速进展性痴呆的患者中未观察到[18F]-AV-1451滞留增加。
- [18F]-AV-1451 PET示踪剂对阿尔茨海默病痴呆相关的配对螺旋丝tau蛋白保持良好特异性。
研究设计与样本
- 在5例散发性克雅氏病患者中进行体内[18F]-AV-1451 PET神经显像,中位年龄66岁(63-74岁)。
- 结果与认知正常者(n=44;中位年龄68岁[63-74岁])和极轻度阿尔茨海默病痴呆者(n=8;中位年龄77岁[63-90岁])比较。
- 所有克雅氏病患者均完成尸检,证实临床诊断并允许表征阿尔茨海默病神经病理改变。
主要发现
- 所有克雅氏氏病患者表现为快速进展性痴呆、典型磁共振脑成像改变和脑脊液总tau升高(中位数=6,519;范围=1,528-13,240 pg/mL)。
- 死亡发生在症状发作后9个月内,从[18F]-AV-1451 PET到尸检的中位间隔为1个月(0.2-3.3)。
- 视觉检查未观察到[18F]-AV-1451滞留的独特模式。
- 克雅氏病患者的标准摄取值比(1.17,1.08-1.36)与认知正常者(1.14,0.84-1.54;p=0.6)无法区分,且远低于阿尔茨海默病者(2.23,1.60-3.04;p≤0.01)。
- 克雅氏病患者和认知正常者在阿尔茨海默病和克雅氏病常受累脑区的[18F]-AV-1451滞留相似;神经病理分析证实所有克雅氏病患者的临床诊断,4例有低水平阿尔茨海默病神经病理改变(A1B1C0),1例有中间水平(A2B2C1/2)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether specific patterns of [18F]-AV-1451 tau-PET retention are observed in patients with autopsy-proven sporadic Creutzfeldt-Jakob disease (CJD). METHODS: In vivo [18F]-AV-1451 PET neuroimaging was performed in 5 patients with sporadic CJD (median age, 66 years [63-74]), and results were compared to cognitively normal (CN) persons (n = 44; median age, 68 years [63-74]) and to participants with very mild Alzheimer disease (AD) dementia (n = 8; median age, 77 years [63-90]). Autopsy was completed in all patients with CJD, confirming the clinical diagnosis and permitting characterization of AD neuropathologic change (ADNC). RESULTS: All patients with CJD presented with rapidly progressive dementia, typical magnetic resonance brain imaging changes, and elevated CSF total tau (median = 6,519; range = 1,528-13,240 pg/mL). Death occurred within 9 months of symptom onset, with a median 1 month (0.2-3.3) interval from [18F]-AV-1451 PET to autopsy. No unique pattern of [18F]-AV-1451 retention was observed on visual inspection. Summary standardized uptake value ratios in patients with CJD (1.17, 1.08-1.36) were indistinguishable from CN persons (1.14, 0.84-1.54; p = 0.6), and well below those of participants with AD (2.23, 1.60-3.04; p ≤ 0.01). [18F]-AV-1451 retention in patients with CJD and CN persons was similar in brain areas frequently affected in AD and CJD. Neuropathologic analysis confirmed the clinical diagnosis in all patients with CJD. Four patients with CJD also had low-level ADNC (A1B1C0); one patient had intermediate-level ADNC (A2B2C1/2). CONCLUSION: Increased [18F]-AV-1451 retention was not observed in patients with rapidly progressive dementia due to sporadic CJD. The [18F]-AV-1451 PET tracer maintains good specificity for paired helical tau filaments associated with AD dementia.
引用
- Day GS, Gordon BA, Perrin RJ, et al. In vivo [18F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease. Neurology. 2018. PMID: 29438042. doi:10.1212/WNL.0000000000005064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。